R&D Trends

The Center for Drug R&D, IRICoR partner

Thursday, May 14, 2015 01:20 PM

The Institute for Research in Immunology and Cancer—Commercialization of Research (IRICoR) at the Université de Montréal (UdeM) and the Center for Drug R&D (CDRD) have initiated collaborations on three new drug development projects. These projects, which address areas of high unmet medical need, are being supported by funding from Merck & Co. to IRICoR.

More... »


Sanofi, Selecta Biosciences extend partnership on synthetic vaccine particle technology

Thursday, May 14, 2015 01:18 PM

Sanofi, in relation to an existing collaboration, has exercised its option to an exclusive license to develop an immunotherapy for the treatment of celiac disease with Selecta Biosciences, a Watertown, Mass.-based clinical stage biotechnology company developing a novel class of targeted antigen-specific immune therapies.

More... »


WHO draws lessons from Ebola to prepare roadmap for future epidemics

Wednesday, May 13, 2015 12:17 PM

The World Health Organization (WHO) has concluded a meeting on Ebola R&D to look at lessons learned from the outbreak and develop a roadmap for future epidemics.

More... »

AstraZeneca inks personalized medicine partnerships with Abbott, Montreal Heart Institute

Wednesday, May 13, 2015 12:07 PM

AstraZeneca has formed collaborations with the Montreal Heart Institute (MHI) in Quebec, Canada, to search the genomes of up to 80,000 patients for genes associated with cardiovascular diseases and diabetes, their complications and treatment outcomes, and with Abbott to develop companion diagnostic tests to identify patients with severe asthma who are most likely to benefit from the investigational biological therapy tralokinumab.

More... »

Eli Lilly, BioNTech form immune system research collaboration

Wednesday, May 13, 2015 11:56 AM

Eli Lilly and Biopharmaceutical New Technologies (BioNTech), a Germany-based immunotherapy company, have entered into a research collaboration to discover novel cancer immunotherapies. The companies will seek to use the power of the body’s own immune system to attack cancer cells and create possible new treatment options for cancer patients.

More... »

The Michael J. Fox Foundation, Imago Pharmaceuticals partner

Monday, May 11, 2015 03:15 PM

The Michael J. Fox Foundation for Parkinson's Research (MJFF) has acquired a library of research tools around the parkin protein from Imago Pharmaceuticals. The Foundation believes these tools—cell lines, plasmids, compounds and more—will accelerate biological study and drug development against this promising disease-modification target.

More... »

UNC-Chapel Hill, GSK partner for HIV cure, launch Qura Therapeutics

Monday, May 11, 2015 02:06 PM

The University of North Carolina at Chapel Hill, a global public research university with experience in HIV basic and clinical research, and GlaxoSmithKline have created the dedicated HIV Cure Center and a jointly owned new company that will focus on discovering a cure for HIV/AIDS. This unique public-private partnership will redefine the traditional way of conducting research and create a new model to seek the breakthroughs needed to tackle a global health issue.

More... »

Juno Therapeutics, Fate Therapeutics collaborate on T cell immunotherapies

Thursday, May 7, 2015 12:19 PM

Juno Therapeutics, based in Seattle, and Fate Therapeutics, headquartered in San Diego, have executed a four-year strategic research collaboration and license agreement to identify and utilize small molecules to modulate Juno's genetically-engineered T cell product candidates to improve their therapeutic potential for cancer patients.

More... »

Report: Total global spending on oncology medicines reached $100B in 2014

Wednesday, May 6, 2015 02:53 PM

Earlier diagnosis, longer treatment duration and increased effectiveness of drug therapies are contributing to rising levels of spending on medicines for cancer care, according to a new report released by the IMS Institute for Healthcare Informatics, a global information and technology services company based in Parsippany, N.J. The report stated total global spending on oncology medicines—including therapeutic treatments and supportive care—reached the $100 billion threshold in 2014, even as the share of total medicine spending of oncologics increased only modestly.

More... »

Flagship Ventures partners with AstraZeneca, Nestlé, Bayer

Wednesday, May 6, 2015 02:48 PM

Flagship Ventures, a venture capital and venture creation firm focused on innovations in healthcare and sustainability, has formed strategic innovation partnerships with AstraZenecaNestlé Health Science and Bayer CropScience. These collaborations will allow Flagship to scale up its unique innovation foundry, VentureLabs, as well as expand its early stage venture funding activities while leveraging the partners' strengths as market leaders.

More... »

CenterWatch
CWWeekly

May 18

Research for All Act reaches Congress for second time seeking gender equality in basic research, clinical trials

MediciGlobal finds fewer trial dropouts among participants who actively pursue enrollment versus those recruited

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

May

Job satisfaction mixed as workload increases
Salaries not keeping pace with rise in work, responsibilities

Gamification moving from early science to patient use
Pharma looking to use games for early diagnosis, recruitment, adherence

Already a subscriber?
Log in to your digital subscription.

Purchase the May issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

April

PSI, INC Research, Chiltern best with sites
Strategic outsourcing prioritizing, improving site relationships

Regulatory compliance an increasing burden on sites
Increased staff time, materials, storage eroding site operating profit

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs